Review of the Last 100 Decisions of the Canadian Commissioner of Patents

Market-Statistics-1160x870

By Claire Palmer, Nov 4th, 2019

The Canadian Commissioner of Patents with the assistance of the Patent Appeal Board (PAB) review patent applications that were rejected by Examiners during prosecution. The PAB is an advisory body that includes a Chair and several senior officials of the Patent Office with previous experience as patent examiners. The members of the PAB have not participated in the prosecution of the application to ensure that the review is impartial.

We have conducted an informal review of the last 100 Commissioner’s decisions to gain insight into what type of rejections are being appealed to the Commissioner of Patents and what an Applicant’s likelihood of success is. The decisions were issued between March 23, 2016 and August 5, 2019.

Out of 100 decisions:

12 of the applications under review ultimately issued to patent.

  • 7 of the 12 cases that ultimately issued to patent, the rejections were not considered justified.
  • 5 of the 12 cases that ultimately issued to patent required PAB directed amendments.
  • Only 1 of the 12 cases that ultimately issued to patent included a subject matter rejection.
  • 7 of the 12 cases that ultimately issued to patent included an obviousness rejection.
  • 7 of the 12 cases related to biological or chemical fields.

88 of the applications under review ultimately did not issue to patent.

  • In almost half of these cases a statutory subject matter rejection was made.
  • In 23 of these cases, the only rejection was the statutory subject matter rejection.
  • 17 of these 23 cases included rejections relating to the meaning of art.
  • 21 of these 23 cases included rejections that the claims were directed to a mere plan.
  • 56 of these cases included an obviousness rejection.

Based on our informal review of the last 100 decisions, we believe that Examiner’s decisions to reject applications are generally in-line with the PAB. We further believe the Patent Office will require clarification from the Federal Court with respect to subject matter rejections.

 

For more information please contact:

Claire Palmer, Senior Patent Agent

T: 613.801.0450

E: This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

 

 

Submit to DiggSubmit to FacebookSubmit to Google BookmarksSubmit to StumbleuponSubmit to TwitterSubmit to LinkedIn

cb photo 91 561829f6d3c22

DR. SUZANNE HOF

Patent Agent


Suzanne focuses on the drafting and prosecuting of biochemical, pharmaceutical, chemical as well as cleantech and green technology patents.MBM read_more_btn

 

MBM logo

About MBM

 The process of invention is complete only with the IP protection provided in law. That's where MBM comes in. We match our clients' creative thinking with the creative protection needed to achieve their goals.Read More About MBM

Clarifications to the Data Protection Guidance Document

Health Canada recently announced that section 2.1 of its Guidance Document re: Data Protection has been amended to clarify that the prior approval of a medicinal ingredient in a drug for veterinary use will not preclude the granting of data protection for a drug for...Read More